Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report) and Roche ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target upped by analysts at JPMorgan Chase & Co. from ...

HC Wainwright restated their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $54.00 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Goldstein highlights Enliven Therapeutics (ELVN), Protagonist (PTGX), and Delcath (DCTH) as top biotech picks. To watch more expert insights and analysis on the latest market action, check out ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...